The global antiviral drugs market size is estimated to be USD 56.81 billion in 2021 and is expected to witness a CAGR of 4.51% during the forecast period. Rising incidence of viral infections such as hepatitis, influenza, corona virus, and Human Immunodeficiency Virus (HIV) is a key driver for global antiviral drugs market growth. Moreover, growth in clinical trials, rising R&D investment, government initiatives for availability of advanced drugs with lesser adverse effects, and changing regulatory measures are other drivers expected to propel the market growth. However, stringent regulatory regulations and lack of skilled research professionals are expected to restrain global growth.
Based on drug class, the market is segmented into reverse transcriptase inhibitors, DNA polymerase inhibitors, neuraminidase inhibitors, protease inhibitors, and others. In 2021, the reverse transcriptase inhibitors segment accounted for the maximum revenue share due to their ability to reduce the rate at which a viral infection spreads and increasing R&D initiatives by pharmaceutical companies. This segment is also expected to grow at the fastest CAGR during the forecast period. DNA polymerase inhibitors segment is expected to witness significant growth during the forecast period.
Based on type, the market is categorized into generics and branded. In 2021, the branded segment accounted for the maximum revenue share as consumers perceive branded medicines to be of higher quality, worldwide. Generic segment is anticipated to grow at fastest CAGR during the forecast period, due to the increasing consumer awareness about the benefits of generic medicine and government initiatives.
Based on application, the market is categorized into hepatitis, HIV, influenza, herpes, and others. Hepatitis segment accounted for the highest revenue in 2021 and is projected to maintain its dominance over the forecast period. Hepatitis is of three types, i.e., A, B, and C and there are many antiviral drugs available to treat each type of hepatitis. The market is driven by increasing prevalence and incidence of varied types of hepatitis. HIV is the fastest growing segment for antiviral drugs due to the presence of a large patient base worldwide.
In 2021, North America accounted for the highest revenue share in the global market and is expected to maintain its dominance during the forecast period. This is attributed to the presence of advanced healthcare infrastructure & large number of pharmaceutical and biotechnology firms and increase in awareness about the importance of antiviral drugs by the government. In the U.S., cutting-edge medical research infrastructure coupled with extensive drug clinical trials are fuelling the growth of antiviral drugs.
Asia Pacific is expected to grow at the fastest CAGR over the forecast period owing to the rising prevalence of antiviral diseases, improving healthcare sector, and rising research & development activities in this region. Competitor Insights Some of the major companies in the antiviral drugs market are Bristol Myers Squibb (U.S.), Gilead Sciences, Inc. (U.S.), Cipla Limited (U.S.), F. Hoffmann-La Roche AG, (Switzerland), Aurobindo Pharma Limited (India), AbbVie Inc. (U.S.), Dr. Reddy's Laboratories (India), Merck & Co., Inc. (U.S.), Johnson & Johnson (U.S.), and GlaxoSmithKline plc (U.K.). The leading players have adopted strategic collaborations, mergers & acquisitions, and novel product development approaches to capture the market share.
This exhaustive research report focuses on market size and forecast at global, segmental, regional and country-level along with key market trends and dynamics from 2021 to 2029. The antiviral drugs market report is categorized into the following segments and subsegments:
By Drug Class
Based on drug class, the market is segmented into reverse transcriptase inhibitors, DNA polymerase inhibitors, neuraminidase inhibitors, protease inhibitors, and others. In 2021, the reverse transcriptase inhibitors segment accounted for the maximum revenue share due to their ability to reduce the rate at which a viral infection spreads and increasing R&D initiatives by pharmaceutical companies. This segment is also expected to grow at the fastest CAGR during the forecast period. DNA polymerase inhibitors segment is expected to witness significant growth during the forecast period.
By Type
Based on type, the market is categorized into generics and branded. In 2021, the branded segment accounted for the maximum revenue share as consumers perceive branded medicines to be of higher quality, worldwide. Generic segment is anticipated to grow at fastest CAGR during the forecast period, due to the increasing consumer awareness about the benefits of generic medicine and government initiatives.
By Application
Based on application, the market is categorized into hepatitis, HIV, influenza, herpes, and others. Hepatitis segment accounted for the highest revenue in 2021 and is projected to maintain its dominance over the forecast period. Hepatitis is of three types, i.e., A, B, and C and there are many antiviral drugs available to treat each type of hepatitis. The market is driven by increasing prevalence and incidence of varied types of hepatitis. HIV is the fastest growing segment for antiviral drugs due to the presence of a large patient base worldwide.
Regional Insights
In 2021, North America accounted for the highest revenue share in the global market and is expected to maintain its dominance during the forecast period. This is attributed to the presence of advanced healthcare infrastructure & large number of pharmaceutical and biotechnology firms and increase in awareness about the importance of antiviral drugs by the government. In the U.S., cutting-edge medical research infrastructure coupled with extensive drug clinical trials are fuelling the growth of antiviral drugs.
Asia Pacific is expected to grow at the fastest CAGR over the forecast period owing to the rising prevalence of antiviral diseases, improving healthcare sector, and rising research & development activities in this region. Competitor Insights Some of the major companies in the antiviral drugs market are Bristol Myers Squibb (U.S.), Gilead Sciences, Inc. (U.S.), Cipla Limited (U.S.), F. Hoffmann-La Roche AG, (Switzerland), Aurobindo Pharma Limited (India), AbbVie Inc. (U.S.), Dr. Reddy's Laboratories (India), Merck & Co., Inc. (U.S.), Johnson & Johnson (U.S.), and GlaxoSmithKline plc (U.K.). The leading players have adopted strategic collaborations, mergers & acquisitions, and novel product development approaches to capture the market share.
This exhaustive research report focuses on market size and forecast at global, segmental, regional and country-level along with key market trends and dynamics from 2021 to 2029. The antiviral drugs market report is categorized into the following segments and subsegments:
Antiviral Drugs Market, By Drug Class (Revenue, 2021-2029, USD Billion)
- Reverse Transcriptase Inhibitors (RTI)
- DNA Polymerase Inhibitors (DPI)
- Neuraminidase Inhibitors (NI)
- Protease Inhibitors (PI)
- Others
Antiviral Drugs Market, By Types (Revenue, 2021-2029, USD Billion)
- Generics
- Branded
Antiviral Drugs Market, By Application (Revenue, 2021-2029, USD Billion)
- Hepatitis
- HIV
- Influenza
- Herpes
- Others
Antiviral Drugs Market, By Region (Revenue, 2021-2029, USD Billion)
North America
- U.S.
- Canada
Europe
- Germany
- France
- U.K.
- Spain
- Italy
- Russia
- Rest of Europe
Asia Pacific
- China
- Japan
- India
- Australia
- South Korea
- Rest of APAC
Latin America
- Brazil
- Mexico
- Argentina
- Rest of LATAM
Middle East & Africa
- South Africa
- Saudi Arabia
- Rest of MEA
Table of Contents
1. Research Methodology
3. Executive Summary
4. Market Dynamics
5. Market Environment Analysis
6. COVID-19 Impact Analysis: Antiviral Drugs Market
7. Market Analysis by Drug class
8. Market Analysis by Application
9. Market Analysis by Type
10. Regional Market Analysis
11. North America Antiviral DrugsMarket
12. Europe Antiviral Drugs Market
13. Asia Pacific Antiviral DrugsMarket
14. Latin America Antiviral DrugsMarket
15. MEA Antiviral DrugsMarket
16. Competitor Analysis
17. Company Profiles
Companies Mentioned
A selection of companies mentioned in this report includes:
- Bristol Myers Squibb (U.S.)
- Gilead Sciences Inc. (U.S.)
- Cipla Limited (U.S.)
- F. Hoffmann-La Roche AG
- (Switzerland)
- Aurobindo Pharma Limited (India)
- AbbVie Inc. (U.S.)
- Dr. Reddy's Laboratories (India)
- Merck & Co. Inc. (U.S.)
- Johnson & Johnson (U.S.)
- GlaxoSmithKline plc (U.K.)
